SkinAware logo SkinAware
Contact Get updates

From awareness to action

AI-powered skin lesion risk awareness, built for real-world access gaps

SkinAware provides analysis to assist with rapid risk assessment and next-step guidance. Designed for smartphone-only workflows so more people can take action sooner, even when dermatology access is limited.

1 death every hour
from melanoma in the U.S.
$13.6B
annual U.S. melanoma cost
+$150k
per patient when detected late

Not medical advice. SkinAware does not diagnose or treat any medical condition, and does not replace evaluation by a healthcare professional. If you are concerned about a lesion, seek medical care.

Why this matters

Access bottlenecks and long wait times can delay evaluation. That delay drives worse outcomes and avoidable costs.

  • Underserved groups experience higher mortality
  • Late detection drives preventable spending
  • Earlier action improves survival

What makes SkinAware different

Many options are not validated, require hardware, or do not fit real care pathways. SkinAware is built for clinically credible triage and follow-through.

Accessible
Smartphone-first workflow
Clinically led
Designed for real-world use
Deployment-ready
Built for low-access settings

Founder story

Why SkinAware exists, and why the product is built around real access constraints.

Too many patients with potentially deadly skin lesions wait months for dermatology skin checks. In low access settings, clinicians are often asked to make calls outside their specialty. That creates risk, delays, and avoidable anxiety. I realized the two ingredients for a better pathway were already in everyone’s pocket: modern smartphone cameras and AI trained on large clinical image datasets. SkinAware is built to turn uncertainty into a clear next step, with sensitivity first triage and an emphasis on follow through. This is not about convenience. It is about equity, urgency, and reducing preventable harm when access is the bottleneck.
Kevin Phelan, MD, FACS • Founder and CEO

How it works

A simple workflow from photo to action. Built to integrate into real care pathways.

1

Image analysis

Take a clear photo with your phone. SkinAware analyzes the image using an ensemble model architecture.

2

Risk stratification

Results are presented as next-step guidance, designed for sensitivity-first triage.

3

Referrals and follow-through

Users can share results with a clinician and access vetted referral options where available.

4

Lesion tracking

Save photos over time to support monitoring and follow-up conversations with clinicians.

Analyzing a lesion photo in the SkinAware app
Image analysis
Routine evaluation recommended result screen
Routine evaluation recommended
Prompt evaluation recommended result screen
Prompt evaluation recommended
Lesion tracking list in the SkinAware app
Lesion tracking
Patent pending. USPTO Application No. 63/920,476.
Talk to us

Who it is for

One product narrative that speaks to consumers and validates credibility for researchers and funders.

Consumers

People who want faster clarity and a practical next step when access is limited.

  • Smartphone-only experience
  • Clear next-step guidance
  • Longitudinal photo tracking

Researchers and clinicians

Partners interested in validation, subgroup performance, and pathway impact.

  • Planned prospective validation
  • Fairness and subgroup measurement
  • Workflow integration and outcomes

Investors and accelerators

A scalable access solution with strong unit economics potential and mission alignment.

  • Large addressable market
  • Clear deployment wedge (low access)
  • Distribution via partners and pilots

Performance focused on real-world triage

Internal cross-testing on the ISIC SLICE-3D dataset (217,000+ smartphone-like photos). All Fitzpatrick skin tones included.

92%
Sensitivity (internal benchmark)
80%
Specificity (internal benchmark)
217k+
Clinical images (smartphone-like)
All tones
Fitzpatrick coverage included

Disclosure: Metrics shown are internal benchmark results and are not FDA-cleared claims. They should not be interpreted as diagnostic performance. Clinical validation and prospective trials are planned.

Growing traction

Deployment momentum

  • Alpha launch completed with 60+ users and strong engagement
  • SkinAware Foundation established with Social Good Fund
  • International pilot conversations initiated (SE Asia, LATAM)

Research and collaboration

  • Melanoma Research Alliance LOI
  • MD Anderson Cancer Center collaboration discussions
  • Kansas University Dermatology collaboration discussions

Technical differentiation

  • Ensemble model architecture (patent pending)
  • Designed for smartphone-only capture
  • Roadmap for expanded lesion types and dermoscopy add-ons

Clinically led, execution focused

A team with experience in melanoma care, public health, and AI product development.

Kyisin Aung, MPH
COO
Public health leader. Multi-site workflow experience. Leads clinical partnerships and Foundation.
Kevin Phelan, MD, FACS
CEO
Surgeon and combat veteran. Leads clinical and regulatory strategy.
Nick Lind, MBA
Lead Engineer
Machine learning and data science. Leads development and model work.
Image analysis
Routine evaluation recommended
Prompt evaluation recommended
Lesion tracking
Interested in advising, piloting, or partnering? We are building a pathway from awareness to action for underserved and low-access communities.
Reach out

FAQ

Clear answers to reduce confusion and manage expectations.

Is SkinAware a diagnostic tool?

No. SkinAware provides analysis to assist with rapid risk assessment and next-step guidance. It does not diagnose or treat any medical condition.

What should a user do if they are worried?

Seek evaluation by a qualified healthcare professional. If there is bleeding, rapid change, or other concerning symptoms, do not wait for an app result.

How do you handle fairness across skin tones?

Internal benchmarks include all Fitzpatrick skin tones in the test dataset. Ongoing validation is planned to measure and improve subgroup performance.

What is the regulatory plan?

SkinAware is built as a sensitivity-first triage and referral tool. We plan staged validation and a longer-term FDA path aligned with intended use and claims.

How can researchers collaborate?

Use the contact form below. We are seeking partners for prospective validation, subgroup performance analysis, and pathway outcome studies.

Contact

For pilots, partnerships, research collaborations, or investor updates.

Email

founder@skinawarehealth.com

Foundation

skinawarefoundation.org

Company

skinawarehealth.com

By submitting, you consent to be contacted. Do not include protected health information.